Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077520 | 0.86 | ADRB2 (0.53) | ADRB2ADRB1ABCB1MEN1KMT2A | |
| SCHEMBL14571133 | 0.82 | ADRB2 (0.51) | ADRB2ADRB1ABCB1MEN1KMT2A | |
| SCHEMBL13077539 | 0.82 | ADRB2 (0.53) | ADRB2ADRB1ABCB1MEN1KMT2A | |
| SCHEMBL14571125 | 0.81 | ADRB2 (0.49) | ADRB2ADRB1ABCB1MEN1KMT2A | |
| SCHEMBL13040064 | 0.81 | ADRB2 (0.41) | ADRB2ADRB1PSMB5 | |
| SCHEMBL14571132 | 0.77 | ADRB2 (0.46) | ADRB2ADRB1ABCB1MEN1KMT2A | |
| SCHEMBL13040066 | 0.76 | ADRB2 (0.43) | ADRB2ADRB1CA12CA1CA2 | |
| SCHEMBL13040059 | 0.75 | ADRB2 (0.50) | ADRB2ADRB1ABCB1MEN1KMT2A | |
| SCHEMBL13040113 | 0.72 | NPY1R (0.36) | ADRB2ADRB1PSMB5 | |
| SCHEMBL13077545 | 0.72 | ADRB2 (0.53) | ADRB2ADRB1ABCB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825263-B2 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20070072854-A1 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | NICOX S.A. (FR) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072854-A1 | Nitrooxyderivatives of carvedilol and other beta blockers as antihypertensive | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ABCB1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.